2) Now we are covering @myESMO #ESMO22 updates on #ADCs in development for #LungCancer #LCSM. Our author is Antonio Passaro MD PhD (@APassaroMD) from @IEOufficiale, Milan in Italy 🇮🇹 pic.twitter.com/GWgziWfkc7
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
3b) This content is intended for healthcare providers. ✔️accreditation statement & faculty disclosures are at https://t.co/0EkFYk4TZx. FOLLOW US for the best in 🫁 education delivered right here on Twitter! pic.twitter.com/nkFdZTAi1m
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
5) Antibody drug conjugates (#ADCs) are a new generation of smart bio-pharmaceutical compounds composed of #monoclonal antibodies linked to cytotoxic drugs. They are among the fastest growing drug classes in #oncology. 👏@ADesaiMD pic.twitter.com/t7HtDaJxNa
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
7) 🆕#ESMO22: Toshihiko et al reported preliminary results of #DS_7300 in advanced solid tumors (Ph1/2, https://t.co/cdAAiluAgR) including #NSCLC & #SCLC. The B7 homologue is overexpressed in a wide range of cancers associated with limited survival. See
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
🔓https://t.co/39u084ITvo pic.twitter.com/MUzSoWtU3e
9) In patients with #NSCLC, 4/5 (80%) had post-baseline reduction in target lesions, with a mDoR of 4.3 months. pic.twitter.com/YVBy2WNQj9
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
11a) Based on these interesting preliminary findings . . . pic.twitter.com/zeHHjfoNsL
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
12) On this specific topic, during #ESMO22, @ajsfurness from @royalmarsdenNHS & Team Leader @ICR_London 🇬🇧 commented these results in an ESMO Daily Reporter article, here 🔗
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
🔓https://t.co/SNtEbdDJPk
14) The results of a Ph1 dose escalation on #HER3_DXd, in EGFR-mutant #LungCancer, published in @CD_AACR by Pasi Jänne (@DanaFarber) ➡️ORR of 39% & mPFS of 8.2mos, w/confirmed clinical activity across a broad range of #HER3 membrane expression. 🔓https://t.co/NYdjcFr4UQ pic.twitter.com/B76p6u8qBV
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
16) Also at #ESMO22, more on the #TROP2 #ADC #Dato_DXd in the #ORCHARD Ph2 platform study in pts with advanced #NSCLC who progressed on 1L #osimertinib therapy. Looking at osimertinib + datopotamab deruxtecan (Dato-DXd), in biomarker non-matched group. https://t.co/cK2l8kpL4W. pic.twitter.com/UG48ZODo8Z
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
17b) Which #ADC is in rapid development for #NSCLC, in particular in #EGFR-resistant setting?
— pulmmed_ce (@Pulmmed_CE) November 2, 2022
19) You're now caught up on the highlights from #ESMO22 on advances on emerging #ADC therapy for #lungcancer (#NSCLC & #SCLC) . Grab your certificate for 🆓CE/#CME at https://t.co/YyNsjVva6I. I am @APassaroMD and I 🙏you for joining us!
— pulmmed_ce (@Pulmmed_CE) November 2, 2022